IP Library Granted Patent US 11,701,435
Granted Patent B2
US 11,701,435 · App. 16/820,066 · Granted Jul 18, 2023

Therapeutic retroviral vectors for gene therapy

Inventors: Philippe Louis Leboulch (Bangkok, TH); Robert Pawliuk (Medford, MA); Karen Westerman (Reading, MA)
Assignees: bluebird bio, Inc.; Massachusetts Institute of Technology
A61K48/0058A01K67/0278A61K38/42C07K14/805C12N15/8509C12N15/86A01K2207/15A01K2217/00A01K2227/105A01K2267/03A61K48/00C07H21/04C12N15/63C12N15/867C12N2510/00C12N2740/15043C12N2740/16011C12N2740/16043C12N2830/008C12N2830/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,701,435
App. No.
16/820,066
Granted
Jul 18, 2023
Kind
B2
Abstract

Provided are improved compositions and methods for achieving gene therapy in hematopoietic cells and hematopoietic precursor cells, including erythrocytes, erythroid progenitors, and embryonic stem cells. Also provided are improved gene therapy methods for treating hematopoietic-related disorders. Retroviral gene therapy vectors that are optimized for erythroid specific expression and treatment of hemoglobinopathic conditions are disclosed.

Claims (34)

1. A hematopoietic stem cell comprising a self-inactivating (SIN) lentiviral vector comprising:

a) a human immunodeficiency virus 1 (HIV-1) 5′ long terminal repeat (LTR), wherein the promoter of the HIV-1 5′ LTR is replaced with a heterologous promoter;

b) an RNA export element;

c) a central polypurine tract or DNA FLAP (cPPT/FLAP);

d) a human β-globin promoter;

e) a human β-globin locus control region (LCR), wherein the β-globin promoter and β-globin LCR are operatively linked to a polynucleotide encoding a human globin;

f) a human β-globin 3′ enhancer element; and

g) a HIV-1 3′ LTR, wherein the 3′ LTR comprises at least one deletion compared to the wild-type HIV-1 3′ LTR.

2. The hematopoietic stem cell of claim 1 , wherein the HIV-1 5′ LTR further comprises a deletion compared to the wild-type HIV-1 5′ LTR.

3. The hematopoietic stem cell of claim 1 , wherein the heterologous promoter is a cytomelagovirus (CMV) promoter.

4. The hematopoietic stem cell of claim 1 , wherein the RNA export element comprises a hepatitis B virus post-transcriptional regulatory element (PRE) or a human immunodeficiency virus (HIV) rev response element (RRE).

5. The hematopoietic stem cell of claim 1 , wherein the HIV-1 3′ LTR comprises a polyadenylation sequence.

6. The hematopoietic stem cell of claim 1 , wherein the SIN lentiviral vector does not comprise an insulator element.

7. The hematopoietic stem cell of claim 1 , wherein the polynucleotide encodes a human β-globin.

8. The hematopoietic stem cell of claim 1 , wherein the polynucleotide encodes a human β A-T87Q -globin.

9. The hematopoietic stem cell of claim 1 , wherein the polynucleotide encodes a human γ-globin.

10. The hematopoietic stem cell of claim 1 , wherein the SIN lentiviral vector further comprises a nucleic acid cassette comprising a suicide gene operably linked to a promoter or a gene for in vivo selection of the cell.

11. A hematopoietic progenitor cell comprising a self-inactivating (SIN) lentiviral vector comprising:

a) a human immunodeficiency virus 1 (HIV-1) 5′ long terminal repeat (LTR), wherein the promoter of the HIV-1 5′ LTR is replaced with a heterologous promoter;

b) an RNA export element;

c) a central polypurine tract or DNA FLAP (cPPT/FLAP);

d) a human β-globin promoter;

e) a human β-globin locus control region (LCR), wherein the β-globin promoter and β-globin LCR are operatively linked to a polynucleotide encoding a human globin;

f) a human β-globin 3′ enhancer element; and

g) a HIV-1 3′ LTR, wherein the 3′ LTR comprises at least one deletion compared to the wild-type HIV-1 3′ LTR.

12. The hematopoietic progenitor cell of claim 11 , wherein the HIV-1 5′ LTR further comprises a deletion compared to the wild-type HIV-1 5′ LTR.

13. The hematopoietic progenitor cell of claim 11 , wherein the heterologous promoter is a cytomelagovirus (CMV) promoter.

14. The hematopoietic progenitor cell of claim 11 , wherein the RNA export element comprises a hepatitis B virus post-transcriptional regulatory element (PRE) or a human immunodeficiency virus (HIV) rev response element (RRE).

15. The hematopoietic progenitor cell of claim 11 , wherein the HIV-1 3′ LTR comprises a polyadenylation sequence.

16. The hematopoietic progenitor cell of claim 11 , wherein the SIN lentiviral vector does not comprise an insulator element.

17. The hematopoietic progenitor cell of claim 11 , wherein the polynucleotide encodes a human β-globin.

18. The hematopoietic progenitor cell of claim 11 , wherein the polynucleotide encodes a human β A-T87Q -globin.

19. The hematopoietic progenitor cell of claim 11 , wherein the polynucleotide encodes a human γ-globin.

20. The hematopoietic progenitor cell of claim 11 , wherein the SIN lentiviral vector further comprises a nucleic acid cassette comprising a suicide gene operably linked to a promoter or a gene for in vivo selection of the cell.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2020
From: LEBOULCH, PHILIPPE; WESTERMAN, KAREN
To: GENETIX PHARMACEUTICALS, INC.
Reel/Frame 053486/0460 →
CHANGE OF NAME Recorded Aug 13, 2020
From: GENETIX PHARMACEUTICALS, INC.
To: BLUEBIRD BIO, INC.
Reel/Frame 053486/0529 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2020
From: BLUEBIRD BIO
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 053486/0551 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2020
From: PAWLIUK, ROBERT
To: GENETIX PHARMACEUTICALS, INC.
Reel/Frame 053486/0815 →
Continuity (10)
Continuation 16130845 · Sep 13, 2018
Division 14700021 · Apr 29, 2015
Division 13242815 · Sep 23, 2011
Continuation 12976078 · Dec 22, 2010
Continuation 11150785 · Jun 9, 2005
Continuation PCTUS0339526 · Dec 11, 2003
Provisional Application 60513312 · Oct 21, 2003
Provisional Application 60475822 · Jun 4, 2003
Provisional Application 60433321 · Dec 13, 2002
Related Publication 20200368370A1 · Nov 26, 2020